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Background: Urban South-Asian’s are predisposed to early onset of type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD). There is an urgent need for country specific primary prevention strategies to address
the growing burden of cardio-metabolic disease in this population. The aim of this clinical trial is to evaluate
whether intensive (3-monthly) lifestyle modification advice is superior to a less-intensive (12 monthly; control
group) lifestyle modification advice on a primary composite cardio-metabolic end point in ‘at risk’ urban subjects
aged between 5-40 years.
Methods/Design: This is an open randomised controlled parallel group clinical trial performed at a single centre in
Colombo, Sri-Lanka. A cluster sampling strategy was used to select a large representative sample of subjects aged
between 5-40 years at high risk of T2DM and CVD for the intervention study. We have screened 23,298 (males 47%
females 53%) healthy subjects for four risk factors: obesity, elevated waist circumference, family history of diabetes
and physical inactivity, using a questionnaire and anthropometry. Those with two or more risk-factors were
recruited to the intervention trial. We aim to recruit 4600 subjects for the intervention trial. The primary composite
cardio-metabolic end point is; new onset T2DM, impaired glucose tolerance, impaired fasting glycaemia, new onset
hypertension and albuminuria, following 5 years of intervention. The effect of the intervention on pre-specified
secondary endpoints will also be evaluated. The study will be conducted according to good clinical and ethical
practice, data analysis and reporting guidelines.
Discussion: DIABRISK-SL is a large population based trial to evaluate the prevalence of diabetes, pre-diabetes and
cardio-metabolic risk factors among young urban Sri-Lankans and the effect of a primary prevention strategy on
cardio-metabolic disease end points. This work will enable country specific and regional cardio-metabolic risk
scores to be derived. Further if the proposed intervention is successful the results of this study can be translated
and implemented as a low-cost primary prevention tool in Sri-Lanka and other low/middle income developing
countries.
Trial registration: The trial is registered with the World Health Organisation and Sri-Lanka clinical trial registry
number SLCTR/2008/003
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Type 2 Diabetes Mellitus (T2DM) and associated cardi-
ovascular complications pose a major health-care bur-
den worldwide and present a significant challenge to
patients, health-care systems, and national economies
[1]. Nearly two thirds of the estimated 285 million peo-
ple with diabetes (predominantly T2DM) live in low and
middle income countries [1,2]. Recent data indicates
that South Asia is one of the major sites of this epi-
demic of T2DM with a projected 72% increase in the
number of subjects with T2DM in the next 20 years [1].
In parallel there is an epidemic of pre-diabetes [impaired
glucose tolerance (IGT) and impaired fasting glycaemia
(IFG)], with prevalence rates between 10-15% reported
in South Asian adult populations [1].
T2DM and IGT are associated with a significantly
increased risk of cardiovascular disease (CVD) with South
Asian’s particularly predisposed to early onset of T2DM
and CVD [1]. In South Asia almost a third of T2DM cases
will be in those aged below 45 years [1]. Both CVD and
T 2 D Mm a ys h a r eac o m m o np a t h o g e n e s i sa n di n d e e d
retain many common risk factors/features [1].
S r iL a n k ai sam i d d l ei n c o m ec o u n t r yi nA s i aw i t ha
population of 20 million. Nearly 40% of Sri Lankans are
aged below 40 years and 25% are aged below 18 years
[3]. There has been a rapid urbanisation in recent dec-
ades with an estimated 30% of the population now living
in urban areas [3]. The most recent national study in
subjects aged over 20 years indicated a population pre-
valence of dysglycaemia (defined as T2DM or IGT or
IFG) of 20% which rose to 30% in urban areas [4]. Phy-
sical inactivity, raised body mass index (BMI) and cen-
tral obesity along with urban living were strongly
associated with the increased risk of dysglycaemia.
The majority of lifestyle modification (LSM) interven-
tion studies/programmes on preventing T2DM have
been done in older pre-diabetic subjects with mean ages
between 45-50 years [5-7]. A recent meta-analysis sug-
gested that in subjects with IGT, the number needed to
treat to prevent one case of T2DM was 10.8 with anti-
diabetic drugs as compared to 6.4 with LSM [8].
Furthermore long term ‘legacy’ benefits of LSM which
can last up to 14 years following the cessation of LSM
have been reported [9,10].
To date there is limited information on the prevalence
of T2DM and cardio-metabolic risk factors in young
urban populations from Sri-Lanka or other similar
South-Asian countries. Moreover the effect of a LSM
programme on cardio-metabolic disease end-points has
not been hitherto evaluated in this unique population.
General objective
The objective of the trial is to test the hypotheses that
intensive (3 monthly) LSM advice will be superior to
less intensive (12 monthly) LSM advice in preventing
cardio-metabolic disease in ‘at risk’ young urban Sri
Lankan subjects.
Primary objective/end-point
The primary objective of the trial is to determine
whether intensive (3 monthly) LSM advice will be
superior to less intensive (12 monthly) LSM advice in
reducing the primary composite cardio-metabolic end
point of new onset T2DM, impaired glucose tolerance,
impaired fasting glycaemia, new onset hypertension and
albuminuria at 5 years.
Secondary objective/endpoints
Secondary end-points include; the individuals compo-
nents of the primary composite end-point, incidence of
metabolic syndrome as defined by the International Dia-
betes Federation (IDF) [11,12], incidence of pre-hyper-
tension as defined by Joint National Committee on
Prevention, Detection, Evaluation, and the Treatment of
High Blood Pressure (JNC-7) [13], regression of IGT
and IFG, [IGT and IFG will be defined as per World
Health Organisation (WHO) and American Diabetes
Association criteria [14,15]] and changes in: weight,
BMI, waist circumference (WC), fasting triglycerides,
fasting high density lipoprotein (HDL) and low density
lipoprotein (LDL) cholesterol, serum creatinine and esti-
mated glomerular filtration rate (GFR), physical activity
as measured by the International physical activity ques-
tionnaire (IPAQ)[16], depression, as measured by PHQ-
9 questionnaire, [17], and psychological stress, as mea-
sured by perceived stress scale [18]. Adherence to diet
and physical activity will be self-reported based on
weekly pattern and evaluated at study visits. The effects
of baseline risk factors on the development of end-
points will also be evaluated in analyses.
Quality of life measures will be evaluated using a vali-
dated short version of the multidimensional WHO
Quality of Life questionnaire (WHOQOL-Bref) [19].
Health economic analyses by the Public Health Depart-
ment University of Colombo with advice and guidance
from Division of Social C a r ea n dP o l i c ya tK i n g ’sC o l -
lege London is an area we plan to develop utilising
models described in recent studies [20].
Methods/Design
Study design
DIABRISK-SL is an open randomised controlled parallel
group clinical trial evaluating the effect of intensive (3-
monthly; study group) vs. less-intensive (12-monthly;
control group) LSM advice on a primary composite car-
dio-metabolic end-point (new onset T2DM, IGT, hyper-
tension, and albuminuria) in ‘at-risk’ young urban
subjects aged between 5-40 years. The two arms of the
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years. Figure 1 details the trial flow chart.
Ethics and Trial Registration
The study is funded by IDF BRIDGES, an IDF project
supported by an educational grant from Eli Lilly Dia-
betes and a grant award from the Diabetes Association
of Sri Lanka (DASL). The study protocol is approved
by Ethical Review Committee of Sri Lanka Medical
Association (ERC 07-010). The trial is registered at Sri
Lanka Clinical Trials Registry (Clinical Trial Registra-





Screening of 5-40 yrs old healthy 
volunteers  
Subjects with 2 or more Risk Factors 
invited to attend for primary 
prevention intervention trial 
Less-intensive Lifestyle Modification 
advice on correct nutrition, proper 
exercise & stress reduction 
Review and advice annually 
  None or one risk factor 
  Diabetes 
  Cardiovascular disease 
  Hypertension 
  Renal disease  
  Any communicable/non-
communicable chronic 
diseases 
  Pregnant 
  On medication for 
diabetes, hypertension & 
dyslipidaemia  
Randomisation  
  Diabetes 
  Cardiovascular disease 
  Hypertension 
  Renal disease  
  Pregnant 
  On medication for 
diabetes, hypertension & 
dyslipidaemia  
Control Group  Intensive LSM  
Intensive Lifestyle Modification 
advice on correct nutrition, proper 
exercise & stress reduction 
Review and advice 3-monthly 
Primary composite cardio-metabolic end-point 
and 
Behavioural changes 
Follow-up of 5 years 
 
Figure 1 Trial flow chart. Figure 1 describes trial flow chart from screening to randomisation and end point evaluation at 5 years.
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We screened a population representative of the general
population of Colombo District, the most populous
u r b a nd i s t r i c ti nS r i - L a n k a ,a g e db e t w e e n5t o4 0y e a r s
to identify the prevalence of four risk-factors namely
first degree family history (FH) of T2DM, physical inac-
tivity, raised BMI and raised WC. The sampling strategy
was designed to provide a sample that was representa-
tive of the age and sex distribution of the general popu-
lation aged between 5-40 years in the Colombo district
[3]. A list of schools, workplaces, universities and com-
munity organisations was made that were representative
of the organizations and population aged between 5 to
40 years obtained from the most recent national census
results. This list comprised of 65 organisations and each
of these organizations was individually approached and
eligible participants were invited to take part in the
screening study. The screening survey took place
between 1
st January 2008 and 30
th June 2009. The age
and sex distribution of the screened population was reg-
ularly compared with the distribution of the reference
population to ensure that the screened population was
representative of the distribution of the general popula-
tion aged between 5 and 40 years in the Colombo dis-
trict. More than 95% of subjects and institutions
approached agreed to participate. Subjects with a known
history of T2DM, CVD, hypertension or diabetes and
pregnant women were excluded from the initial sample.
Subjects on lipid lowering drugs or anti-diabetic or anti-
hypertensive drugs were also excluded.
Subjects with any active communicable or non-com-
municable chronic disease (NCD) such as cancer,
asthma or other forms of chronic lung disease, depres-
sion, and tuberculosis were also excluded. A screening
questionnaire (see additional files 1) was used to deter-
mine first degree family history of T2DM and the physi-
cal activity of the individual participants. Further
information regarding socio-demographic factors was
also collected.
T h es c r e e n i n gs t u d ya i m e dt oi d e n t i f yf o u rr i s k - f a c -
tors: physical inactivity (<30 minutes continuous exer-
cise for <3 days/week), raised WC (central obesity)
defined as WC in subjects between 5-17 yrs ≥91
th per-
centile, 18-40 yrs: females ≥80 cm and males ≥90 cm,
first degree FH of T2DM and raised BMI defined in
subjects aged 5-18 yrs of a BMI value greater than inter-
nationally standardized age and sex specific percentile
cutoffs and between 18-40 yrs as BMI ≥23 kg/m
2
[21,22]. These four factors were chosen on the basis of a
pilot study that identified these risk-factors as being
highly prevalent in 1239 subjects aged below 40 years
with a new diagnosis of T2DM who attended the
National Diabetes Centre in Colombo between 2005-
2007 and are supported by recent data from comparable
South Asian and Sri Lankan populations [1,4,22,23].
Inclusion Criteria for primary prevention intervention trial
Subjects aged 5-40 years with two or more risk factors
for cardio-metabolic disease. The risk factors for selec-
tion included two or more of the following;






￿ Subjects with no or one identifiable risk factor
￿ Subjects with diagnosed end-points (T2DM, CVD,
hypertension and renal disease)
￿ Subjects on any form of medication used for the
treatment of diabetes, hypertension, renal disease or
dyslipidaemia
￿ Any active communicable or NCD such as cancer,
asthma or other forms of chronic lung disease,
depression, tuberculosis.
￿ Pregnant women
During the primary prevention intervention trial
￿ Subjects who reach one or more of the following
cardio-metabolic end-points; T2DM, CVD, hyperten-
sion, and albuminuria.
￿ Subjects initiated on any form of medication used
for the treatment of diabetes, hypertension, renal
disease or dyslipidaemia by their family physician or
other medical physician.
￿ Pregnancy at any stage of the study
Randomisation
Subjects who satisfy the selection criteria will be rando-
mised into two intervention group using a computer
generated randomisation schedule/sequence (SPSS 10.0)
prepared by an independent party (Department of Sta-
tistics and Public Health Colombo University). Rando-
misation was performed sequentially using a SPSS
programme function which enables this process and is
supervised by an independent statistician from the
Department of Statistics and Public Health at Colombo
University, Sri Lanka.
Procedures
The following procedures and measurements will be
performed at baseline prior to randomisation to one of
the two groups.
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France) and taken to the closest 0.1 cm, and weight is
measured without footwear in light clothing to the near-
est 100 g with an electronic weighing scale (Seca
France). Both instruments are calibrated weekly. BMI is
calculated as weight in kilograms divided by height
squared in meters. WC is measured using a graduated
measuring tape (Seca France), calibrated weekly, with a
locking device to the nearest 0.1 cm. WC is taken at the
mid-point between the iliac crest and the last rib in
expiration. Blood pressure is measured by automatic
oscillometry from the non-dominant arm after 5 min-
utes rest with the mean of two measurements recorded
(Riester Ri-Champion Riester, Jungingen, Germany).
WHO approved growth charts for male and female chil-
dren will be used [24].
Fasting plasma glucose and a standard 2-hour 75 g
oral glucose tolerance test (OGTT) is performed in
adults and glucose solution 1.75 g/kg body weight, to a
m a x i m a ld o s eo f7 5gi sg i v e nt ot h o s eb e l o w1 6y e a r s
following a 12-hour fast as per WHO guidelines [14].
Plasma Glucose, total cholesterol, high density density
lipoprotein (HDL), low density lipoprotein (LDL), trigly-
cerides and serum creatinine will be measured by enzy-
matic colorimetry (Vitros MS 250, Ortho Clinical
Diagnostics, Johnson and Johnson, Co, Rochester USA).
Fasting plasma insulin will be measured using radioim-
munoassay (Immulite, Siemens, Surrey, UK), which has
as e n s i t i v i t yo f4μU/ml (<24 pmol/l) and intra and
interassay coefficients of variation <8%. Insulin resis-
tance will be calculated using the homeostasis model
assessment of insulin resistance (HOMA-IR) [25]. Urine
albumin to creatinine ratio will be measured by immu-
noturbidemtry (Vitros 5,1 FS Chemistry System, Ortho-
Clinical Diagnostics, Johnson and Johnson Company,
Hampshire, United Kingdom) from an early morning
urine sample. In subjects below 18 years the Schwartz
equation will be used to estimate glomerular filtration
rate (GFR) from serum creatinine values [26] and in
subjects above 18 years the Modification of Diet in
Renal Disease (MDRD) Study equation will be used to
estimate GFR [27].
Intervention and goals
I n t e n s i v eL S Mg r o u p :T h em a i ng o a l so ft h ei n t e n s i v e
group delivered three monthly on an individual basis
are:
Dietary advice and support: individualised advice is
given on the need to have a well balanced food intake
and to maintain appropriate body weight in those with
normal BMI and WC. In subjects with a raised (age and
gender appropriate) BMI and WC a goal of >5% weight
loss is set concordant to targets in recent studies [5-8].
Dietary advice on avoiding a high intake of food
containing simple sugars, refined carbohydrates and
high saturated fats (total fat intake <20 g/day) and
advice to increase intake of healthy natural foods which
are fibre-rich-whole grains, legumes, vegetables and
fruits is given. A list of refined foods to be avoided is
provided. Subjects are advised on the importance of reg-
ular meals and to avoid delaying or missing meals.
Exercise; Subjects with physical inactivity at baseline
are advised to increase physical activity to at least 30
minutes of continuous exercise a day for more than 5
days of the week. Individualised exercise advice is given
depending on the needs and facilities available to the
subject. Children are advised on need to play at least for
1 hour every day. All subjects are advised to minimise
sedentary activity such as watching television. For chil-
dren, the LSM advice will be given to the parent and
the child jointly. To ensure that the intervention does
not hamper normal growth, assessment of the child’s
growth (height and weight) will be performed at each
visit and these measures compared to the previous
values on the child’s growth chart; and if there is any
medical and or parental concerns regarding growth, the
child will be referred to a paediatrician for further eva-
luation and assessment.
T h ed i e t a r ya n de x e r c i s eg o a l sa r ec o m p a r a b l et o
those set in the Indian Diabetes Prevention Programme
(IDPP) [6]. All subjects have a three monthly telephone
contact to assess progress and reiterate goals. The total
number of one to one contacts is 4 per year. The basis
of LSM advice is made on the transtheoretical model of
behaviour change [28] which postulates that individuals
are at different stages of readiness to adopt a new beha-
viour and that individuals are required to progress
through various ‘stages of change’. Evidence suggests
that providing individualised interventions tailored to a
subject’s stage of behaviour change i.e. stage matched, as
done in this study, are more effective than providing the
same intervention to all subjects [29].
Control group: Less intensive (annual) lifestyle advice:
Identical dietary and exercise advice as outlined above
are given to all subjects in the control group; however
this is done on a 12 monthly basis. The goals and tar-
gets set for diet and exercise are identical to those in
the intensive group but these are evaluated and rein-
forced annually in one individualised face to face contact
session with an educator.
Statistical methods and power calculation
Approximately 2300 subjects with ≥2 risk-factors are
required in each group (4600 subjects in total) to detect
a 25% relative risk reduction at 5 years on the primary
composite cardio-metabolic end-point of new onset
T2DM, IGT, IFG, hypertension, albuminuria, renal and
CVD events with intensive LSM. The study is powered
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assuming a 15% incidence of the primary end-point in
the control group and including allowance for 25%
drop-out of subjects. The proposed 25% relative risk
reduction of the composite outcome is derived from the
effects of intensive LSM programme reducing the rela-
tive risk of new onset T2DM in South Asian IGT
patients [1,6].
T h e r ew i l lb eap r e - s p e c i f i e di n t e r i ma n a l y s i so ft h e
composite primary and secondary endpoints at 2 years,
as requested by one of the funding bodies (IDF
B R I D G E S ) .T h i sa n a l y s i sw ill be performed by an inde-
pendent statistician and the trial investigators will
remain blinded to the full data analyses and interim
results. All data related to interim analysis will directly
forwarded to funding body by the independent statisti-
cian and will be strictly confidential and not for public
dissemination/publication.
Descriptive statistics will be used for the analysis of
demographic and clinical features of the cohort. Two-
sided t-tests and chi-square (c
2) tests will be used to
analyze the comparison between the groups at baseline
and during follow-up. Survival curves will be calculated
to estimate the cumulative incidence of the composite
primary end-point and secondary end-points. The differ-
ence between the groups in the primary end-point will
be tested by means of the two-sided log-rank test. All
analyses of end-points are based on the intention-to-
treat principle. Analyses will be performed using
STATA software version 10 (Stata Corp, College Sta-
tion, TX, USA).
Definition of primary cardio-metabolic end-points
▪ New onset T2DM as indicated by either a fast-
ing plasma glucose of ≥7.0 mmol/l and/or a 2-hr
plasma glucose concentration of ≥11.1 mmol/l dur-
ing an annual follow-up confirmed by repeat 75 g
OGTT as per World Health Organization (WHO)
criteria [14] or initiation anti-diabetic treatment by
the subject’s family physician following confirma-
tory tests.
▪ New onset IGT is defined as a plasma fasting glu-
cose <7.0 mmol/l and 2-h glucose 7.8-11.0 mmol/l
and IFG as fasting plasma glucose between 6.1 to.9
mmol/l or 5.6 to 6.9 mmol/l [14,15].
▪ New onset hypertension is defined as mean bra-
chial blood pressure from 2 readings taken following
5m i n u t e sr e s t≥140/90 mmHg or initiation of anti-
hypertensive treatment commenced by the subject’s
family physician as per JNC-7 criteria [13]. In those
below 18 years hypertension is defined as blood
pressure that is, on repeated measurement, at the
95
th percentile or greater adjusted for age, height,
and sex [13].
▪ New onset albuminuria is defined as urine albu-
min/creatinine ratio ≥2.5 mg/mmol in males and
≥3.5 mg/mmol in females from early morning sam-
ple confirmed on one repeat test.
▪ New onset renal impairment is defined as esti-
mated GFR <60 ml/min or doubling of serum creati-
nine from baseline.
▪ CVD events are defined as fatal and not fatal
events of Myocardial infarction (MI): Congestive
heart failure (CHF): death due to clinical, radiologi-
cal or post-mortem evidence of CHF, Stroke, vascu-
lar revascularisitation and admission for unstable
angina.
Independent advisory and data monitoring group
An independent external expert advisory and monitor-
ing board has been formulated which includes two
experts from the MV-Diabetes Research Centre and
Hospital in Chennai India (IDPP trial site) and one Sri
Lankan expert from the Department of Community
medicine, University of Colombo. This board will regu-
larly review the progress of the DIABRISK-SL study and
will also independently adjudicate on CVD events.
Discussion
This study will be the first large population based study
to determine the effect of a primary prevention LSM
strategy on cardio-metabolic risk in a young urban
population. This work will enable the characterisation of
the natural history of cardio-metabolic disease in a
unique at-risk population hitherto not studied in such
detail or number. Importantly research project such as
DIABRISK-SL enhance awareness of diabetes and asso-
ciated risks amongst the study subjects, their friends
and families. Such public health promotion is invaluable
in countries with limited financial resources. The pro-
posed intervention programme if successful may be
implemented as a low-cost primary prevention tool in
Sri Lanka and other similar low and middle income
countries.
Our study will also determine the prevalence of
T2DM, pre-diabetes, and cardio-metabolic risk factors
in young urban Sri Lankans. We have also aimed to
develop a method for identifying a sample at increased
risk of T2DM and CVD for a randomised controlled
trial. We hope to show that a simple screening strategy
based on self-reported physical inactivity, family history
of T2DM in first degree relatives, as well as obesity and
increased WC provides an efficient method for identify-
ing a sample with a high frequency of cardio-metabolic
risk. More recently the entity of metabolic syndrome as
a disease syndrome has been questioned [30]. However
it is irrefutable that individual risk factors for CVD and
T2DM cluster and inter-relate [11,12]. Furthermore in
its purest form, as we will report with the exclusion of
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description of the individual risk components, it is a
pre-morbid condition that could be useful in developing
country specific public health intervention strategies
[30].
This study will have the largest urban cohort below
the age of 40 years in South Asia evaluated for cardio-
metabolic risk. Our results will raise awareness of
growing burden of T2DM and obesity in developing
countries that is of major public health and economic
importance and which requires urgent remedial
actions [1,31]. The results of DIABRISK-SL will help
advise and assist in the formulation of a national pol-
icy and guidance document for combating T2DM and
associated non-communicable diseases in Sri Lanka
[32].
Additional material
Additional file 1: Screening questionnaire. Screening questionnaire
used to determine first degree family history of T2DM and the physical
activity of the individual participants.
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